Guardian Pharmacy Services, Inc. (GRDN) Stock Price & Analysis
Guardian Pharmacy Services, Inc. (GRDN) closed at USD 39.59 on Thursday, October 22, 2026, up 1.56% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 38.98; the Oct 22, 2026 session ranged USD 39.31–39.97 on volume of 252,887 shares. Market capitalization is $2.51B, with a 52-week range of USD 26.34–48.33 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:01 UTC.
Also available as compact Markdown for AI agents: nexqual.com/GRDN.md
Key facts (GRDN)
- Last four reported quarters (through Jun 30, 2026): revenue $1.46B, net income $65.9M (4.5% margin) (SEC filings).
- Valuation: P/E 38.0x.
- Analysts: Buy (mean 1.86 on a 1–5 scale) (7 analysts), mean target USD 49.86 (range 47–52).
- Total return with dividends: 1Y +41.2% vs S&P 500 +14.9%; 5Y +123.0% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 0.31, revenue estimate $366M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (GRDN)
| USD | FY2024 | FY2025 | TTM |
|---|---|---|---|
| Revenue | $1.23B | $1.45B | $1.46B |
| Gross profit | $244M | $293M | — |
| Operating income | -$62.9M | $72.7M | $85.4M |
| Net income | -$110M | $49.2M | $65.9M |
| Free cash flow | $43.3M | $86.8M | — |
| Gross margin | 19.9% | 20.2% | — |
| Operating margin | -5.1% | 5.0% | 5.8% |
| Net margin | -9.0% | 3.4% | 4.5% |
| Revenue growth | — | +17.9% | — |
| Cash + short-term investments | $4.7M | $65.6M | — |
| Total debt | $0K | $0K | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (GRDN)
P/E 38.0x · P/S 1.7x · P/B 9.7x · Earnings yield 2.63%
Analysts (GRDN)
Consensus Buy (mean 1.86 on a 1–5 scale), 7 analysts; mean target USD 49.86 (low 47, high 52).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-23 | Keybanc | Initiated | Overweight | $52 |
| 2026-09-21 | Truist Securities | Target raised | Buy | $47 → $51 |
| 2026-08-07 | Oppenheimer | Target raised | Outperform | $43 → $49 |
Total return (dividends reinvested) (GRDN)
| 1Y (from 2025-10-23) | 5Y (from 2024-09-23) | |
|---|---|---|
| Total return | +41.2% | +123.0% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +41.4% | +47.1% |
| Volatility (annualized) | 40.9% | 42.6% |
| Max drawdown | -18.8% (Sep 2026→Oct 2026) | -26.1% (Dec 2024→Mar 2025) |
GRDN company outlook (results filed Aug 6, 2026)
- “We also continued to expand profitability, reflecting the benefits of scale, purchasing leverage and improved operating efficiency." Burke continued, "Our second-quarter performance, together with our outlook for the remainder of the year, gives us the confidence to raise our 2026 guidance." FY 2026 Outlook – Updating Guidance The guidance below excludes any future acquisitions.”
- “Updated Guidance Previous Guidance Revenue $ 1.43 billion - $1.45 billion $ 1.40 billion -$1.42 billion Adjusted EBITDA $ 129 million -$131 million $ 122 million -$127 million M&A and Greenfields Subsequent to quarter-end, Guardian completed the acquisition of Wellness Concepts, a long-term care pharmacy based in Grottoes, Virginia.”
Analysts expect $365.8M for the current quarter, 74.6% below the midpoint of the company's guidance ($1.44B).
Quoted word-for-word from the SEC 8-K results press release.
GRDN analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.31 | $0.30 | +4.2% | $365.8M | 7 |
| Next quarter (ends Dec 2026) | $0.41 | $0.41 | +1.1% | $387.8M | 7 |
| Current fiscal year (ends Dec 2026) | $1.30 | $1.26 | +3.3% | $1.44B | 7 |
| Next fiscal year (ends Dec 2027) | $1.43 | $1.36 | +5.6% | $1.53B | 7 |
Key Statistics (as of October 23, 2026 at 10:01 UTC)
| Price | USD 39.59 |
|---|---|
| Change | ▲ 1.56% (up) |
| Previous Close | USD 38.98 |
| Open | USD 39.38 |
| Day Range | USD 39.31 – 39.97 |
| 52-Week Range | USD 26.34 – 48.33 |
| Volume | 252,887 shares |
| Market Cap | $2.51B |
| Exchange | NYQ |
Technical Analysis (GRDN)
Nexqual's technical model rates GRDN "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:01 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.08 (neutral) |
| vs SMA50 | Below (USD 40.83) |
| MACD | -0.52 (negative) |
Analyst Ratings (GRDN)
Wall Street analysts rate GRDN "Buy" based on 7 analysts, with a mean price target of USD 49.86 (range USD 47–52), per Nexqual as of October 23, 2026 at 10:01 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 49.86 |
| High Target | USD 52 |
| Low Target | USD 47 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (GRDN)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 0.31 |
| Revenue Estimate | $365.76M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.29 vs est 0.26 ▲ beat |
| 2026-03-31 | USD 0.29 vs est 0.24 ▲ beat |
| 2025-12-31 | USD 0.37 vs est 0.27 ▲ beat |
| 2025-09-30 | USD 0.25 vs est 0.24 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:01 UTC.
Financials & Fundamentals (GRDN)
| Total Revenue | $1.46B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +2.20% |
| Gross Margin | +21.63% |
| Operating Margin | +3.48% |
| Profit Margin | +4.50% |
| ROE | +30.42% |
| Debt / Equity | 0.15 |
| Current Ratio | 1.65 |
| Total Cash | $89.81M |
| Total Debt | $39.27M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | $86.84M (6.0% of revenue) |
Source: Nexqual, October 23, 2026 at 10:01 UTC.
Financial Health Score (GRDN)
Nexqual rates Guardian Pharmacy Services, Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 10:01 UTC.
| Growth | Strong — Revenue +18% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 22%, operating 3% (last 12 months) |
| Balance Sheet | Strong — $66M cash and investments, no debt (Dec 2025, SEC) |
| Cash Flow | Solid — FCF $87M (FY ended Dec 2025, 10-K), 6% margin |
| Efficiency | Strong — ROE 30%, ROA 13.4% |
Ownership (GRDN)
| Insider Ownership | +57.45% |
|---|---|
| Institutional Ownership | +61.15% |
| Shares Outstanding | 63.32M |
| Float | 22.38M |
| Short % of Float | +4.90% |
Source: Nexqual, October 23, 2026 at 10:01 UTC.
Leadership (GRDN)
Guardian Pharmacy Services, Inc. is led by Fred P. Burke, CEO, President & Director, per Nexqual as of October 23, 2026 at 10:01 UTC.
| CEO, President & Director | Fred P. Burke |
|---|---|
| COO & Director | David K. Morris |
| Senior VP & CFO | Will Mudd |
| Head of Investor Relations & Senior Director | Ashley Stockton |
| Vice President of Human Resources | Vicki Crabtree |
Major Backers & Investors (GRDN)
Notable institutional backers of Guardian Pharmacy Services, Inc. include FMR, LLC, Wellington Management, Fidelity, according to Nexqual as of October 23, 2026 at 10:01 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 6.51% |
| Wellington Management | 3.47% |
| Fidelity | 2.66% |
| Woodline Partners LP | 2.62% |
| Valiant Capital Management, L.P. | 2.38% |
| T. Rowe Price | 2.24% |
| Boston Partners | 1.98% |
| Franklin Resources, Inc. | 1.94% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 3.16% |
| Vanguard Group | 2.77% |
Source: Nexqual, October 23, 2026 at 10:01 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BKD | Brookdale Senior Living Inc. | USD 10.19 | ▲ 1.09% |
| MD | Pediatrix Medical Group, Inc. | USD 29.55 | ▲ 5.16% |
| ADUS | Addus HomeCare Corporation | USD 122.67 | ▲ 4% |
| AVAH | Aveanna Healthcare Holdings Inc | USD 13.32 | ▲ 2.54% |
| ACHC | Acadia Healthcare Company, Inc. | USD 31.88 | ▲ 1.43% |
| SGRY | Surgery Partners, Inc. | USD 15.9 | ▲ 3.25% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:01 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt